At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of Three Doses of AR-13324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
In Brief
A Phase 2 clinical trial evaluating AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, and 2 other interventions for Ocular Hypertension and Open Angle Glaucoma. Completed, enrolled 85 participants across 11 sites.
Detailed Summary
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days. The first dose and last dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated in the clinic throughout the study.
Study Details
Timeline
Interventions
Administered to study eye, once daily (QD) in the morning (AM) for 7 days
Administered to study eye, QD AM for 7 days
Administered to study eye, QD AM for 7 days
Administered to study eye, QD AM for 7 days